Equities analysts expect Cascadian Therapeutics Inc (NASDAQ:CASC) to post earnings of ($0.29) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Cascadian Therapeutics’ earnings. Cascadian Therapeutics posted earnings of ($0.47) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 38.3%. The firm is expected to issue its next earnings report on Thursday, March 8th.
According to Zacks, analysts expect that Cascadian Therapeutics will report full year earnings of ($1.27) per share for the current financial year, with EPS estimates ranging from ($1.53) to ($1.14). For the next year, analysts expect that the company will post earnings of ($1.03) per share, with EPS estimates ranging from ($1.22) to ($0.69). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Cascadian Therapeutics.
Cascadian Therapeutics (NASDAQ:CASC) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.01. During the same period last year, the firm earned ($0.09) earnings per share.
Separately, Zacks Investment Research upgraded Cascadian Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a report on Monday, November 13th. Three analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. Cascadian Therapeutics has a consensus rating of “Hold” and a consensus target price of $5.63.
A number of large investors have recently added to or reduced their stakes in CASC. Dimensional Fund Advisors LP lifted its stake in Cascadian Therapeutics by 423.0% during the third quarter. Dimensional Fund Advisors LP now owns 511,899 shares of the biopharmaceutical company’s stock worth $2,094,000 after purchasing an additional 414,019 shares in the last quarter. State Street Corp lifted its stake in Cascadian Therapeutics by 1,113.7% during the second quarter. State Street Corp now owns 411,299 shares of the biopharmaceutical company’s stock worth $1,527,000 after purchasing an additional 377,410 shares in the last quarter. Vanguard Group Inc. lifted its stake in Cascadian Therapeutics by 24.1% during the second quarter. Vanguard Group Inc. now owns 1,767,681 shares of the biopharmaceutical company’s stock worth $6,567,000 after purchasing an additional 343,838 shares in the last quarter. Northern Trust Corp lifted its stake in Cascadian Therapeutics by 415.5% during the second quarter. Northern Trust Corp now owns 382,469 shares of the biopharmaceutical company’s stock worth $1,420,000 after purchasing an additional 308,270 shares in the last quarter. Finally, P.A.W. Capital Corp acquired a new position in Cascadian Therapeutics during the third quarter worth $982,000. Institutional investors own 80.33% of the company’s stock.
Cascadian Therapeutics (NASDAQ:CASC) traded up $0.15 on Wednesday, reaching $4.07. The company had a trading volume of 271,162 shares, compared to its average volume of 285,624. Cascadian Therapeutics has a 12-month low of $3.18 and a 12-month high of $4.97. The firm has a market capitalization of $198.20, a PE ratio of -3.01 and a beta of 2.30.
WARNING: “” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/1806112-2/1806112.html.
Cascadian Therapeutics Company Profile
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.